The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | Assessing I-SABR in early or recurrent non-small cell lung cancer
Joe Chang, MD, PhD, The University of Texas MD Anderson Cancer Centre, Houston, TX, shares the results of the Phase II trial (NCT03110978) of stereotactic ablative radiotherapy (SABR) combined with nivolumab, an immune checkpoint inhibitor, in early stage or recurrent isolated non-small cell lung cancer (NSCLC). The study demonstrated that multiple doses of nivolumab alongside SABR (I-SABR) significantly increased event-free survival, including a lower incidence of local, regional, distant or secondary malignancies. Dr Chang emphasises the importance of these results in demonstrating the effectiveness of immunotherapy in NSCLC. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
